within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA04_Dolasetron;

model Dolasetron_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 1.2833333333333333e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 600,
    Vdp = 0.00275,
    k12 = 6.3e-06,
    k21 = 6.3e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dolasetron_1</td></tr><tr><td>ATC code:</td><td>A04AA04_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.0</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dolasetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting associated with chemotherapy, radiation, and surgery. It is currently approved for medical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Coppes, MJ, et al., &amp; Pratt, CB (1999). Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. <i>Journal of pediatric hematology/oncology</i> 21(4) 274–283. DOI:<a href=\"https://doi.org/10.1097/00043426-199907000-00007\">10.1097/00043426-199907000-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10445889/\">https://pubmed.ncbi.nlm.nih.gov/10445889</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A04AA04_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dolasetron_1;
